MilWealth Group’s Neurocrine Biosciences NBIX Stock Holding History

MilWealth Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10	Closed	-$852	–	129
2021 Q4	$852	Hold	10	–	–	﹤0.01%	154
2021 Q3	$960	Buy	+10	New	+$945	﹤0.01%	164

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MilWealth Group's NBIX Position: Q1 2022 in Review

MilWealth Group sold out of Neurocrine Biosciences (NBIX) in Q1 2022, closing a stake of 10 shares — an estimated $852 sold.

MilWealth Group first reported a position in NBIX in Q3 2021 and held it in 2 quarters. The position peaked at $960 in Q3 2021. 426 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

MilWealth Group reported no remaining Neurocrine Biosciences position as of Q1 2022 after selling out during the quarter.
MilWealth Group sold 10 Neurocrine Biosciences shares in Q1 2022, an estimated $852.
MilWealth Group first reported a position in Neurocrine Biosciences in Q3 2021 and held it in 2 quarters.
MilWealth Group's Neurocrine Biosciences position peaked at $960 in Q3 2021.
426 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on MilWealth Group's 13F filing for Q1 2022, filed 9 May 2023.